8-KOther EventsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Corporate Update (Oct 19, 2011)

Filed October 19, 2011For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) announced on October 18, 2011, the pricing of a significant $400 million offering of 1.875% convertible senior notes due October 1, 2016. This move aims to raise capital for the company's ongoing operations and development. The notes are exclusively offered to qualified institutional buyers under Rule 144A. Investors should note the convertible nature of these notes, which can be exchanged for cash and/or Regeneron's common stock, with an initial conversion price representing a substantial premium over the then-current market price. Furthermore, Regeneron has implemented a convertible note hedge and warrant strategy to mitigate potential dilution from the note conversion. The hedge transactions cover the shares underlying the notes, while the warrants are set at a strike price significantly above the stock's closing price on October 17, 2011. These financial instruments are designed to manage the impact of share price fluctuations and potential share issuances on the company's equity structure.

Key Highlights

  • 1Regeneron priced a $400 million offering of 1.875% convertible senior notes due October 1, 2016.
  • 2The offering is restricted to qualified institutional buyers under Rule 144A.
  • 3The notes are convertible into cash and/or Regeneron common stock at the company's option.
  • 4The initial conversion price of approximately $84.02 per share represents a 30% premium over the October 17, 2011 closing price of $64.63.
  • 5Regeneron entered into convertible note hedge transactions to cover the shares underlying the notes, aimed at mitigating dilution.
  • 6Warrant transactions were also executed with an initial strike price of approximately $103.41, representing a 60% premium over the stock's closing price.
  • 7The company has the option to settle the warrant transactions in shares or cash.

Frequently Asked Questions

The primary purpose of this offering is to raise capital for Regeneron Pharmaceuticals. While not explicitly stated, such capital is typically used to fund ongoing research and development, clinical trials, general corporate purposes, and business expansion.

The convertible notes can be converted into Regeneron's common stock, which could lead to an increase in the number of outstanding shares. However, Regeneron has entered into hedge and warrant transactions to help mitigate potential dilution and manage the impact on its share price.

The initial conversion price of approximately $84.02 per share represents a 30% premium over the stock's closing price on October 17, 2011. This indicates that the notes are designed to be attractive to investors based on the expectation of future stock price appreciation above $64.63 per share.

These transactions are financial instruments designed to offset the potential dilutive effect of the convertible notes if they are converted. The hedge transactions cover the underlying shares, and the warrants provide Regeneron with the right (but not obligation) to buy back shares or receive cash at a predetermined price, helping to manage the cost of potential share issuance.